Preferred Label : LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine
OST31-164;
NCIt definition : A cancer vaccine containing a live, highly attenuated strain of the Gram-positive
bacterium Listeria monocytogenes (LmddA) encoding a fusion protein composed of a chimeric
peptide comprised of three highly immunogenic epitopes of the human tumor-associated
antigen (TAA) HER2/neu (chHER2) fused to a non-hemolytic fragment of the immunostimulant
listeriolysin O (LLO) protein, with potential immunostimulatory and antineoplastic
activities. Upon administration of the LmddA-LLO-chHER2 vaccine OST31-164, the LmddA
is taken up by phagocytic cells; then the listeriolysin portion of the expressed LLO-chHER2
can form pores in the phagolysosomes and the fusion protein can escape into the cytosol.
In turn, the LLO-chHER2 is processed and presented to the immune system by major histocompatibility
complex (MHC) I on the phagocytic cells. Antigen presentation activates the immune
system to exert an immune response involving the recruitment and activation of T-lymphocytes
against HER2-expressing tumor cells, and inhibits tumor-infiltrating T regulatory
cells (Tregs) and myeloid-derived suppressor cells (MDSCs). This eventually results
in tumor cell lysis. HER2/neu, a tyrosine kinase receptor belonging to the epidermal
growth factor receptor (EGFR) family, is overexpressed in various tumor cell types.;
Molecule name : ADXS31-164; ADXS 31164; OST31 164; OST-HER2; OST31164; ADXS-HER2;
Origin ID : C121541;
UMLS CUI : C5554530;
Semantic type(s)
- concept_is_in_subset
- has_target
